Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance

BJU International

Volumn 100, Issue 3, 2007, Pages 544-551

  Pickles, Tom ^a,d   Ruether, J Dean ^b,c   Weir, Lorna ^a,c   Carlson, Linda ^b,d   Jakulj, Fabijana ^b   Hack, Thomas F ^c   Butler, Lorna ^d   Degner, Lesley F ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Active surveillance; Anxiety; Expectant management; Prostate neoplasms; Stress; Uncertainty

Indexed keywords

ANXIETY; ARTICLE; CANCER SCREENING; HUMAN; MENTAL DISEASE; PATIENT EDUCATION; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSOCIAL CARE; SOCIAL PSYCHOLOGY; TREATMENT PLANNING;

AGED; ANXIETY DISORDERS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; DECISION MAKING; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SOCIAL SUPPORT; STRESS, PSYCHOLOGICAL;

EID: 34547618086     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06981.x     Document Type: Article

References (59)

1. Ferlay J. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancerbase. Lyon : IARC Press, 2002
2. National Comprehensive Cancer Network. Risk Stratification Scheme - Prostate Cancer. Available at: http://www.nccn.org/professionals/physician_gls/ PDF/prostate.pdf. Accessed March 2007
3. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006 94 : 1361 8
4. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 24
5. Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994 8 : 439 43
6. Cooperberg MR, Broering JM, Litwin MS et al. CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004 171 : 1393 401
7. Roemeling S, Roobol MJ, Postma R et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006 50 : 475 82
8. Bill-Axelson A, Holmberg L, Ruutu M et al. Scandinavian Prostate Cancer Group Study No. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 84
9. Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003 92 (Suppl. 2 106 11
10. Canadian Cancer Society. Canadian Cancer Statistics- 2006. Available at: http://www.cancer.ca/ccs/internet/standard/0,3182,3278_14279langId-en,00.html. Accessed March 2007
11. Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol 2004 172 : 515 9
12. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999 54 : 503 8
13. Parker C. Active surveillance of early prostate cancer: rationale, initial results and future developments. Prostate Cancer Prostatic Dis 2004 7 : 184 7
14. Donovan J, Hamdy F, Neal D et al. ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003 7 : 1 88
15. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005 23 : 8165 9
16. Harlan SR, Cooperberg MR, Elkin EP et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003 170 : 1804 7
17. Roemeling S, Roobol MJ, de Vries SH et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007 51 : 1244 51
18. Lazarus R, Folkman S. Stress, Appraisal and Coping. New York : Springer, 1984
19. Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum 2001 28 : 551 60
20. Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int 2002 90 : 56 61
21. Balderson N, Towell T. The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. Br J Health Psychol 2003 8 : 125 34
22. Kronenwetter C, Weidner G, Pettengill E et al. A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial. Cancer Nurs 2005 28 : 99 107
23. Chapple A, Ziebland S, Herxheimer A, McPherson A, Shepperd S, Miller R. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU Int 2002 90 : 257 64
24. Charles C, Whelan T, Gafni A, Reyno L, Redko C. Doing nothing is no choice: lay constructions of treatment decision-making among women with early stage breast cancer. Sociol Health Illness 1998 20 : 71 95
25. Hedestig O, Sandman PO, Widmark A. Living with untreated localized prostate cancer: a qualitative analysis of patient narratives. Cancer Nurs 2003 26 : 55 60
26. Clark JA, Inui TS, Silliman RA et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003 21 : 3777 84
27. Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 2003 30 : 303 9
28. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology 2004 63 : 751 6
29. Mazur DJ, Hickam DH. Patient preferences for management of localized prostate cancer. West J Med 1996 165 : 26 30
30. Carvalhal GF, Smith DS, Ramos C et al. Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening. J Urol 1999 162 : 113 8
31. Stark DP, House A. Anxiety in cancer patients. Br J Cancer 2000 83 : 1261 7
32. Lofters A, Juffs HG, Pond GR, Tannock IF. 'PSA-itis': knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol 2002 168 : 2516 20
33. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002 167 : 1664 9
34. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998 82 : 342 8
35. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004 171 : 1520 4
36. Roth AJ, Rosenfeld B, Kornblith AB et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer 2003 97 : 2910 8
37. Latini DM, Hart SL, Knight SJ et al. Cancer anxiety predicts time to active treatment for men with localized prostate cancer on active surveillance: Data from CaPSURE. ASCO 2006 Prostate Cancer Symposium 2006. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/? vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=42&index=y&abstractID=20009. Accessed March 2007
38. Lintz K, Moynihan C, Steginga S et al. Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic. Psychooncology 2003 12 : 769 83
39. Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2000 164 : 1973 7
40. Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care 2001 39 : 243 53
41. Arredondo SA, Downs TM, Lubeck DP et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol 2004 172 : 1830 4
42. Altwein J, Ekman P, Barry M et al. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. Urology 1997 49 (Suppl. 66 76
43. Steineck G, Helgesen F, Adolfsson J et al.; Scandinavian Prostate Cancer Group Study No. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002 347 : 790 6
44. Zeliadt SB, Ramsey SD, Penson DF et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 2006 106 : 1865 74
45. Diefenbach MA, Dorsey J, Uzzo RG et al. Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol 2002 20 : 55 62
46. Fowler FJ Jr., McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000 283 : 3217 22
47. Cancerbackup. Overview: screening. Available at: http://www.cancerbackup. org.uk/Aboutcancer/Screening/Overview. Accessed March 2007
48. Gray RE, Fitch MI, Phillips C, Labrecque M, Klotz L. Presurgery experiences of prostate cancer patients and their spouses. Cancer Pract 1999 7 : 130 5
49. Hack TF, Pickles T, Bultz BD, Dean Ruether J, Degner LF. Impact of providing audiotapes of primary treatment consultations to men with prostate cancer: a multi-site, randomized, controlled trial. Psychooncology 2006 September 21 : Epub ahead of print
50. Feldman-Stewart D, Brundage MD, Van Manen L, Svenson O. Patient-focussed decision-making in early-stage prostate cancer: insights from a cognitively based decision aid. Health Expect 2004 7 : 126 41
51. Bailey DE, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs 2004 27 : 339 46
52. Mishel MH. Reconceptualization of the uncertainty in illness theory. Image J Nurs Sch 1990 22 : 256 62
53. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med 2003 65 : 571 81
54. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004 29 : 448 74
55. Penedo FJ, Dahn JR, Molton I et al. Cognitive-behavioral stress management improves stress-management skills and quality of life in men recovering from treatment of prostate carcinoma. Cancer 2004 100 : 192 200
56. Levi F, Lucchini F, Negri E, La Vecchia C. Recent trends in prostate cancer mortality in the European Union. Epidemiology 2000 11 : 612
57. National Cancer Institute, USA. SEER Results. Available at: http://canques.seer.cancer.gov. Accessed March 2007
58. Montie JE. Counseling the patient with localized prostate cancer. Urology 1994 43 (Suppl. 36 40
59. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 95 : 868 78